Short answer
ARVINAS, INC. (ARVN) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $500,000 (down 98.8% year over year) with net income of −$54M.
Q3 2026 key financials · XBRL
- Revenue
- $500,000
- −98.8% YoY · −99.8% QoQ
- Net income
- −$54M
- −53.6% YoY · −131.8% QoQ
- Operating margin
- -11820.0%
- EPS (diluted)
- −$0.82
- −70.8% YoY · −131.5% QoQ
Source: XBRL data from the ARVINAS, INC. (ARVN) Q3 2026 10-Q on SEC EDGAR. USD.
ARVINAS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0.5M, down $41.4M YoY from $41.9M, reflecting nonrecurring collaboration and milestone revenue
- Q3 net loss $53.9M vs $35.1M YoY, with R&D expense $46.9M vs $64.7M
- Best R&D growth: ARV-393 expense $5.8M vs $2.6M; worst: vepdegestrant expense $0 vs $14.2M
- Cash, equivalents, restricted cash and marketable securities $558.9M vs $685.4M at December 31, 2025; operating cash use $127.9M
- Funding runway into second half of 2028; ARV-102 PSP trial on clinical hold pending FDA review
Risk Factors
- New risk triggered by AI deployment: AI and machine learning use in PROTAC discovery introduces data, cybersecurity, intellectual-property and operational exposure
- Most materially updated risk: Rigel now controls VEPPANU pricing, reimbursement, sublicensing and ex-U.S. regulatory decisions
- Regulatory risk: EU AI Act became fully effective in August 2026, increasing high-risk AI compliance obligations
- Operational risk: VEPPANU commercialization depends entirely on Rigel’s funding and execution
- Financial risk: No committed external funding source before substantial product-sale revenue generation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARVINAS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.